Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-07-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: protocoldefinedtumorprioranti
  Phrases that lowered it: subjectssubjectopen labelfemalestudy
• Sponsor's past termination rate: 4.1% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 22.2% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 95.2% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 442 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 1004 (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects NCT00955773 · started 2009 · scored riskier than 44% of active trials completed
• Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. NCT01248858 · started 2010 · scored riskier than 31% of active trials terminated
• Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors NCT01324258 · started 2011 · scored riskier than 40% of active trials completed
• Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma NCT00687622 · started 2008 · scored riskier than 20% of active trials completed
• Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation NCT01647659 · started 2012 · scored riskier than 17% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.